Amgen - AMGN Stock Forecast, Price & News

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Trading Up 1.5 %

NASDAQ:AMGN opened at $252.09 on Thursday. The firm has a market capitalization of $134.67 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 2.03 and a beta of 0.56. Amgen has a 1-year low of $198.64 and a 1-year high of $258.45. The business's 50-day moving average price is $244.81 and its two-hundred day moving average price is $240.17. The company has a current ratio of 1.53, a quick ratio of 1.17 and a debt-to-equity ratio of 14.76.

Amgen (NASDAQ:AMGN - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.25. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.53 billion. Amgen had a net margin of 24.92% and a return on equity of 218.34%. Amgen's quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the firm earned $4.38 EPS. On average, equities analysts expect that Amgen will post 17.42 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th will be issued a dividend of $1.94 per share. The ex-dividend date is Wednesday, August 17th. This represents a $7.76 annualized dividend and a yield of 3.08%. Amgen's dividend payout ratio is presently 65.76%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AMGN shares. Oppenheimer restated a "buy" rating and set a $290.00 target price on shares of Amgen in a research report on Wednesday. Morgan Stanley upped their price objective on shares of Amgen from $239.00 to $253.00 and gave the stock an "equal weight" rating in a research note on Friday, July 15th. Mizuho boosted their target price on Amgen from $202.00 to $208.00 in a report on Tuesday, May 10th. TheStreet cut Amgen from a "b+" rating to a "c+" rating in a report on Wednesday, April 27th. Finally, SVB Leerink assumed coverage on Amgen in a report on Monday, May 23rd. They set a "market perform" rating and a $256.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $245.14.

Insider Buying and Selling at Amgen

In related news, Director R Sanders Williams sold 600 shares of the stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now directly owns 5,501 shares of the company's stock, valued at approximately $1,375,250. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.46% of the company's stock.